Browsing ICR Divisions by author "Oyen, Willem"
Now showing items 1-20 of 34
-
18F-FDG PET/CT in Detecting Metastatic Infection in Children.
Kouijzer, IJE; Blokhuis, GJ; Draaisma, JMT; Oyen, WJG; de Geus-Oei, L-F; et al. (2016-04)Purpose of the report Metastatic infection is a severe complication of bacteremia with high morbidity and mortality. The aim of this study was to investigate the diagnostic value of 18F-FDG PET combined with CT (FDG PET/CT) ... -
18F-FDG PET/CT in Local Ablative Therapies: A Systematic Review.
Aarntzen, EHJG; Heijmen, L; Oyen, WJG (2018-04)Driven by the continuous improvement in the accuracy of cross-sectional imaging, image-guided minimally invasive local ablative therapies have received incremental interest over the past few years. In this article, we ... -
18F-fluorodeoxyglucose positron-emission tomography combined with computed tomography as a diagnostic tool in native valve endocarditis.
Kouijzer, IJE; Berrevoets, MAH; Aarntzen, EHJG; de Vries, J; van Dijk, APJ; et al. (2018-08)OBJECTIVE:The aim of the study was to investigate the value of F-fluorodeoxyglucose positron-emission tomography combined with computed tomography (F-FDG-PET/CT) in diagnosing native valve endocarditis (NVE). PATIENTS AND ... -
A comparison of the diagnostic value of MRI and 18 F-FDG-PET/CT in suspected spondylodiscitis.
Smids, C; Kouijzer, IJE; Vos, FJ; Sprong, T; Hosman, AJF; et al. (2017-02)Purpose The purpose of this study was to evaluate the diagnostic value of 18 F-fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (PET/CT scan) and magnetic resonance imaging (MRI) in diagnosing ... -
Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor.
Desar, IME; Braam, PM; Kaal, SEJ; Gerritsen, WR; Oyen, WJG; et al. (2016-12) -
Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules.
de Koster, EJ; de Geus-Oei, L-F; Dekkers, OM; van Engen-van Grunsven, I; Hamming, J; et al. (2018-04)Indeterminate thyroid cytology (Bethesda III and IV) corresponds to follicular-patterned benign and malignant lesions, which are particularly difficult to differentiate on cytology alone. As ~25% of these nodules harbor ... -
Dosimetry in clinical radionuclide therapy: the devil is in the detail.
Giammarile, F; Muylle, K; Delgado Bolton, R; Kunikowska, J; Haberkorn, U; et al. (2017-11) -
EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems.
Kaalep, A; Sera, T; Oyen, W; Krause, BJ; Chiti, A; et al. (2018-03)PURPOSE:From 2010 until July 2016, the EANM Research Ltd. (EARL) FDG-PET/CT accreditation program has collected over 2500 phantom datasets from approximately 200 systems and 150 imaging sites worldwide. The objective of ... -
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Van Cutsem, E; Cervantes, A; Adam, R; Sobrero, A; Van Krieken, JH; et al. (2016-08)Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved ... -
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.
Boellaard, R; Delgado-Bolton, R; Oyen, WJG; Giammarile, F; Tatsch, K; et al. (2015-02)The purpose of these guidelines is to assist physicians in recommending, performing, interpreting and reporting the results of FDG PET/CT for oncological imaging of adult patients. PET is a quantitative imaging technique ... -
FDG-PET/CT Limited to the Thorax and Upper Abdomen for Staging and Management of Lung Cancer.
Arens, AIJ; Postema, JWA; Schreurs, WMJ; Lafeber, A; Hendrickx, BW; et al. (2016-01)Purpose This study evaluates the diagnostic accuracy of [F-18]-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) of the chest/upper abdomen compared to the generally performed scan from head ... -
Fever of Unknown Origin: the Value of FDG-PET/CT.
Kouijzer, IJE; Mulders-Manders, CM; Bleeker-Rovers, CP; Oyen, WJG (2018-03)Fever of unknown origin (FUO) is commonly defined as fever higher than 38.3°C on several occasions during at least 3 weeks with uncertain diagnosis after a number of obligatory investigations. The differential diagnosis ... -
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.
Bozkurt, MF; Virgolini, I; Balogova, S; Beheshti, M; Rubello, D; et al. (2017-08)Purpose & methods Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline ... -
In Vivo Characterization of 4 68Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models.
Lobeek, D; Franssen, GM; Ma, MT; Wester, H-J; Decristoforo, C; et al. (2018-08)αvβ3 integrins play an important role in angiogenesis and cell migration in cancer and are highly expressed on the activated endothelial cells of newly formed blood vessels. Here, we compare the targeting characteristics ... -
Performance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy.
Grootjans, W; Usmanij, EA; Oyen, WJG; van der Heijden, EHFM; Visser, EP; et al. (2016-06)Background and purpose This study evaluated the use of total lesion glycolysis (TLG) determined by different automatic segmentation algorithms, for early response monitoring in non-small cell lung cancer (NSCLC) patients ... -
PET/CT with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion
Hekman, MCH; Rijpkema, M; Aarntzen, EA; Mulder, SF; Langenhuijsen, JF; et al.Based on the high expression of Carbonic Anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study ... -
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
Muselaers, CHJ; Boers-Sonderen, MJ; van Oostenbrugge, TJ; Boerman, OC; Desar, IME; et al. (2016-05)Unlabelled Despite advances in the treatment of metastatic clear cell renal cell carcinoma (ccRCC), there is still an unmet need in the treatment of this disease. A phase 2 radioimmunotherapy (RIT) trial with lutetium 177 ... -
Positron Emission Tomography/Computed Tomography with <sup>89</sup>Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.
Hekman, MCH; Rijpkema, M; Aarntzen, EH; Mulder, SF; Langenhuijsen, JF; et al. (2018-09)Based on the high expression of carbonic anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study ... -
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer.
Du, Y; Carrio, I; De Vincentis, G; Fanti, S; Ilhan, H; et al. (2017-09)Purpose Radium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option ... -
Radioimmunotherapy for delivery of cytotoxic radioisotopes - current status and challenges
Oyen, W; kramer-marek, G